Ypsomed Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a YPHDF research report →
About the company
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices.
- CEO
- Simon Michel
- IPO
- 2022
- Employees
- 2,644
- HQ
- Burgdorf, CH
Price Chart
- Market Cap
- $5.65B
- P/E
- 22.04
- P/S
- 6.46
- P/B
- 6.51
- EV/EBITDA
- 14.52
- Div Yield
- 1.22%
- Gross Margin
- 43.04%
- Op Margin
- 25.26%
- Net Margin
- 30.36%
- ROE
- 28.54%
- ROIC
- 14.23%
- Revenue
- $730.98M · -2.39%
- Net Income
- $221.93M · 153.62%
- EPS
- $16.31 · 154.45%
- Op Income
- $246.07M
- FCF YoY
- 87.33%
- 52W High
- $535.75
- 52W Low
- $354.92
- 50D MA
- $368.36
- 200D MA
- $399.90
- Beta
- 0.77
- Avg Volume
- 22.912
Get TickerSpark's AI analysis on YPHDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our YPHDF coverage
Recent articles, reports, and earnings notes.
No research on YPHDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate YPHDF report →Similar companies
Peers in the same neighborhood.